Cisplatin, Paclitaxel, and Everolimus in Treating Patients With Metastatic Breast Cancer

DISEASE CHARACTERISTICS:

• Histologically confirmed invasive mammary carcinoma
• Stage IV disease
• Basal-like disease (triple-negative, hormone-refractory, HER2-negative)
• No locally recurrent breast cancer
• No symptomatic brain metastases
• Patients with a history of brain metastases are eligible provided they are clinically stable for > 3 weeks after completion of radiotherapy and are not taking steroids or therapeutic anticonvulsants that are cytochrome P450 3A4 (CYP3A4) modifiers
• Patients with asymptomatic brain metastases are eligible provided they are not taking prophylactic anticonvulsants that are CYP3A4 modifiers

PATIENT CHARACTERISTICS:

• Pre- or post-menopausal
• European Cooperative Oncology Group (ECOG) performance status 0-1
• Life expectancy ≥ 6 months
• Absolute neutrophil count (ANC) ≥ 1,000/mm^3
• Platelet count ≥ 100,000/mm^3
• Creatinine ≤ 1.5 times upper limit of normal (ULN)
• Total bilirubin ≤ 1.5 times ULN (≤ 3 times ULN in the presence of liver metastasis)
• Direct bilirubin will be measured in patients with Gilbert syndrome
• serum glutamate oxaloacetate transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) ≤ 1.5 times ULN (≤ 3 times ULN in the presence of liver metastasis)
• Alkaline phosphatase ≤ 3 times ULN (in the presence of liver metastasis)
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment
• Able to swallow and retain oral medication
• No malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel
• No concurrent uncontrolled illness including, but not limited to, any of the following:
• Ongoing or active infection requiring parenteral antibiotics
• Impaired lung function (chronic obstructive pulmonary disease or lung conditions requiring oxygen therapy)
• New York Heart Association class III-IV congestive heart failure
• Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within the past 6 months
• Uncontrolled hypertension (systolic BP > 180 mm Hg or diastolic BP > 100 mm Hg, found on 2 consecutive measurements separated by a 1-week period and despite adequate medical support)
• Clinically significant cardiac arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or requires treatment [grade 3 according to NCI Common Toxicity Criteria for Adverse Events v3.0])
• Uncontrolled diabetes (hyperosmolar state, ketoacidosis, etc.)
• Psychiatric illness or social situations that would compromise patient safety or limit compliance with study requirements including maintenance of a compliance/pill diary
• No symptomatic neuropathy ≥ grade 2
• No other invasive cancer within the past 5 years except for completely resected basal cell or squamous cell carcinoma of the skin or successfully treated cervical carcinoma in situ
• No hypersensitivity to paclitaxel or drugs using the vehicle Cremophor, Chinese hamster ovary cell products, or other recombinant human antibodies
• No history of hepatitis B or C

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics
• Recovered from prior therapy
• Prior total cumulative life-time dose of doxorubicin ≤ 360 mg/m^2 or epirubicin ≤ 640 mg/m^2
• No more than 4 prior chemotherapy treatments in the metastatic setting (not including endocrine therapy or single-agent biologic therapy)
• At least 2 weeks since prior investigational drugs
• At least 14 days since prior and no concurrent herbal or dietary supplements
• At least 14 days since prior and no concurrent CYP3A4 inducers
• At least 7 days since prior and no concurrent CYP3A4 inhibitors
• Concurrent radiotherapy to painful bone metastases or areas of impending bone fracture allowed provided radiotherapy is initiated before study entry
• No other concurrent anticancer therapy (chemotherapy, radiotherapy, surgery, im